GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewon Pharmaceutical Co Ltd (XKRX:003220) » Definitions » Debt-to-Revenue

Daewon Pharmaceutical Co (XKRX:003220) Debt-to-Revenue : 0.32 (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Daewon Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Daewon Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩120,752 Mil. Daewon Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩66,489 Mil. Daewon Pharmaceutical Co's annualized Revenue for the quarter that ended in Dec. 2024 was ₩580,282 Mil. Daewon Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.32.


Daewon Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Daewon Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewon Pharmaceutical Co Debt-to-Revenue Chart

Daewon Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.35 0.24 0.28 0.31

Daewon Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.26 0.35 0.30 0.32

Competitive Comparison of Daewon Pharmaceutical Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Daewon Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daewon Pharmaceutical Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daewon Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Daewon Pharmaceutical Co's Debt-to-Revenue falls into.


;
;

Daewon Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Daewon Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(120751.577 + 66488.971) / 598162.353
=0.31

Daewon Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(120751.577 + 66488.971) / 580281.636
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Daewon Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Daewon Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Daewon Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
229-3 Yongdap-dong, Seongdong-gu, Seoul, KOR, 133-850
Daewon Pharmaceutical Co Ltd is active in the healthcare sector in Korea. Its main business involves antipyretics, respiratory drugs, cardiovascular drugs, and neuromuscular drugs. It also produces a range of health foods such as multivitamins. The company operates on a global basis.

Daewon Pharmaceutical Co Headlines

No Headlines